Which Decongestants Are Effective? Why the FDA Wants to Pull a Popular Medicine Ingredient [CNET News]
GoodRx Holdings, Inc. - Class A (GDRX)
Company Research
Source: CNET News
While phenylephrine is still considered safe, a scientific panel that advises the FDA found last year that it doesn't actually work at decongesting or "unstuffing" your nose when it's taken by mouth in over-the-counter products. Phenylephrine is still considered effective in nasal spray form. Importantly, the FDA's notice from this week doesn't affect the sale of any medication right now; the FDA is seeking public comment on its proposed rule. If, after more consideration, the health agency decides to change the rules around phenylephrine oral over-the-counter products, it will be removed as an active ingredient and drugmakers will need to change their product formulas or pull them altogether. "Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this next step in the process to propose removing oral phenylephrine because it is not effective as a nasal decongestant," Dr. Patrizia Cavazzoni, director of the FDA's Center for
Show less
Read more
Impact Snapshot
Event Time:
GDRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GDRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GDRX alerts
High impacting GoodRx Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
GDRX
News
- Gen Z's expensive drug habit: More want brand-name meds that are 79% more expensive [Yahoo! Finance]Yahoo! Finance
- Gen Z's expensive drug habit: More want brand-name meds that are 79% more expensive [Fortune]Fortune
- What Is The Medicare Donut Hole Coverage Gap? [Forbes]Forbes
- Healthy Returns: What to know about Trump's NIH funding cuts [CNBC]CNBC
- LOKKER Appoints Geoffrey Golliher as Chief Technology Officer to Advance Data Privacy Innovation for Enterprises, Cyber Insurers and Law Firms [Yahoo! Finance]Yahoo! Finance
GDRX
Earnings
- 11/7/24 - Beat
GDRX
Sec Filings
- 2/13/25 - Form SCHEDULE
- 2/11/25 - Form 4
- 2/5/25 - Form 3
- GDRX's page on the SEC website